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Pathfinder Cells Provide A Novel Therapeutic
Intervention For Acute Kidney Injury
Liane M. McGlynn,1 Kathrin Eller,2,3 Alasdair I. MacDonald,1 Alan MacIntyre,1 David Russell,4
Christian Koppelstaetter,2 R.W. Davies,1 and Paul G. Shiels1
Abstract
Pathfinder cells (PCs) are a novel class of adult-derived cells that facilitate functional repair of host tissue. We
used rat PCs to demonstrate that they enable the functional mitigation of ischemia reperfusion (I/R) injury in a
mouse model of renal damage. Female C57BL/6 mice were subjected to 30min of renal ischemia and treated
with intravenous (i.v.) injection of saline (control) or male rat pancreas-derived PCs in blinded experimentation.
Kidney function was assessed 14 days after treatment by measuring serum creatinine (SC) levels. Kidney tissue
was assessed by immunohistochemistry (IHC) for markers of cellular damage, proliferation, and senescence
(TUNEL, Ki67, p16ink4a, p21). Fluorescence in situ hybridization (FISH) was performed to determine the presence
of any rat (i.e., pathfinder) cells in the mouse tissue. PC-treated animals demonstrated superior renal function at
day 14 post-I/R, in comparison to saline-treated controls, as measured by SC levels (0.13mg/dL vs. 0.23mg/dL,
p < 0.001). PC-treated kidney tissue expressed significantly lower levels of p16ink4a in comparison to the control
group ( p = 0.009). FISH analysis demonstrated that the overwhelming majority of repaired kidney tissue was
mouse in origin. Rat PCs were only detected at a frequency of 0.02%. These data confirm that PCs have the
ability to mitigate functional damage to kidney tissue following I/R injury. Kidneys of PC-treated animals
showed evidence of improved function and reduced expression of damage markers. The PCs appear to act in a
paracrine fashion, stimulating the host tissue to recover functionally, rather than by differentiating into renal
cells. This study demonstrates that pancreatic-derived PCs from the adult rat can enable functional repair of
renal damage in mice. It validates the use of PCs to regenerate damaged tissues and also offers a novel
therapeutic intervention for repair of solid organ damage in situ.
Introduction
Acute kidney injury (AKI) is a condition of variedetiology associated with high rates of mortality and
morbidity. Clinically, AKI is characterized by a rapid dete-
rioration in kidney function resulting in a failure to maintain
fluid, electrolyte, and acid–base homoeostasis (Renal Asso-
ciation Guidelines1). Recent figures suggest that approxi-
mately 5%–20% of critically ill patients experience an episode
of AKI during the course of their illness.1 Following cardiac
surgery, up to 30% of patients can develop AKI.2 Whereas
the overall incidence of AKI following cardiac surgery may
remain low, the associated mortality is high. Data have
shown that an increase of only 0.3mg/dL in serum creati-
nine levels is an independent predictor of morbidity and
mortality in patients undergoing cardiac surgery.3 AKI is
generally the consequence of an ischemic, or toxic, insult that
results in damage to the renal proximal tubule cells. Renal
ischemia/reperfusion (I/R) injury is frequently associated
with AKI and is particularly pertinent in transplantation
(renal replacement therapy). I/R injury can have a detri-
mental effect on organ function post-transplant, resulting in
delayed graft function, acute rejection, and late graft dys-
function.
Despite this, there is no gold standard treatment for re-
pairing and restoring kidney function. Renal replacement
therapy (RRT) is currently the best treatment modality for
those with end-stage renal disease (ESRD). Renal dialysis is a
common first line of defense, but it is unsatisfactory in terms
of outcome (only 10.5% of patients survive 10 years on
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dialysis), patient quality of life, and cost. Transplantation,
while life saving, is compromised by the ongoing critical
shortfall in available donor organs and episodes of organ
rejection and dysfunction. Renal disease is a growing medi-
cal problem, with high levels of associated morbidity and
mortality. Currently, there are 1:2,000 people within the
European Union and 1:1,000 in the United States, with
chronic kidney disease (CKD) who would benefit from a
transplant. In the United States and European Union over
100,000 patients are awaiting a kidney transplant, but only
20,700 transplants are performed annually.
A preferred treatment option would be to initiate repair of
kidney damage as early as possible, and hence prevent, or at
least postpone, progression to ESRD or organ dysfunction
post-transplant. This is particularly pertinent to the nature of
molecular deterioration in the damaged organ, as either a
consequence of disease or pathology following RRT. In each
instance, the organ shows accelerated bioaging, with an ac-
cumulation of senescent cells, correlated with increased
CDKN2A (p16ink4a) expression.4–6 One hypothesis suggests
that replacement of such cells is required to enhance function
and regenerate the organ. Precedence for this hypothesis
exists in a recent report that indicates that the removal of
p16ink4a-expressing cells from tissues delays the onset of age-
related pathologies.7
Cellular therapy is thus an attractive option to regenerate
damaged kidneys in situ. However, the kidney is a particu-
larly morphologically complex organ, requiring approxima-
tely 26 terminally differentiated cell types to be organized
into a highly ordered, spatially organized structure.8–10
Consequently, the proliferative potential of the kidney is low
in comparison to other tissues. Despite this, the kidney does
have the capacity for self-regeneration and repair, with the
ability to recover from insults such as acute tubular necrosis.11
Current candidate cellular therapies to tackle kidney in-
jury are all in their infancy. These have included bone mar-
row stem cells (BMSCs) and multi-potent stromal cells/
mesenchymal stem cells (MSCs). BMSCs, although a prom-
ising candidate for treating renal disease, have produced
equivocal results. Unfractionated BMSCs have been shown
to differentiate into endothelial and mesangial cells in a
model of progressive glomerulosceloris.12 There is further
evidence that they can also differentiate into tubular epi-
thelial cells and podocytes.11 However, the use of un-
fractionated BMSCs produces very low rates of tubular cell
replacement and limited functional improvement.8,13
Several studies using MSCs have indicated an improve-
ment in renal structure and increased tubular cell prolifera-
tion, accompanied by a concomitant recovery in renal
function, as measured by lower blood urea nitrogen (BUN)
levels.14 This has also been substantiated in a study of
glycerol-induced acute renal failure (ARF).15 MSCs have
been demonstrated to produce essential growth factors, such
as vascular endothelial growth factor (VEGF), hepatocyte
growth factor (HGF), and insulin-like growth factor-1
(IGF-1), which are associated with enhanced proliferation,
improved survival, and decreased apoptosis.8,16 In addition,
these factors have been shown to have a specific role in
kidney function and repair.11 The release of these factors by
MSCs may therefore promote proliferation and survival of
tubular epithelial cells, while minimizing apoptosis. Re-
cently, adipose-derived MSCs have been shown to protect
rat kidneys following I/R injury via reduction of oxidative
stress and suppression of the inflammatory response, while
concomitantly promoting angiogenesis. Transcription levels
of genes encoding anti-inflammatory, anti-oxidative, and
anti-apoptotic biomarkers were higher in rats treated with
adipose-derived MSCs following I/R injury than in con-
trols.17 The hypothesis that MSCs may promote repair by
reducing the levels of oxidative stress following insult is
further supported by a report indicating that MSC treatment
reduced levels of superoxide dismutase and glutathione
peroxidase following I/R injury in rats.18
A further candidate cell type for renal repair comprises
adult parietal epithelial multipotent progenitors (APEMPs),
which have been identified in the Bowman capsule of the
adult kidney.19 These are reported to display multi-
differentiation potential and self-renewal capacity. Mice
treated with APEMPs have improved recovery from ARF, as
measured by lowered BUN levels, with smaller areas of ne-
crotic kidney tissue, suggesting that APEMPs have the ability
to repair tubular damage.20
An alternative cell-based approach to treat kidney injury
entails the use of pathfinder cells (PCs).21,22 PCs have been
demonstrated to initiate repair of host tissue across a species
barrier in the pancreas.22 In a mouse streptozotocin-induced
diabetes model, both rat and human PCs have been dem-
onstrated to induce regeneration of the damaged host
(mouse) pancreas22 in a paracrine fashion and to restore
long-term normal glycemia. No immunosuppression was
administered with either rat or human PC treatments, as
preliminary experiments were consistent with the PC cells
being immunologically null. PC cell administration in the
presence of 20mg/kg cyclosporin did not affect the capacity
of PC cells to reduce blood glucose levels.22
Therefore, we have hypothesized that PCs may similarly
be able to facilitate repair in other organs. Given the in-
creasing incidence of kidney disease, the lack of treatment
options and suitable cell therapies, we considered the kidney
to be an attractive organ for testing the capacity of the PCs to
stimulate regeneration. We undertook this experiment with a
view to achieving solely a therapeutic end point, namely
restoration of normal kidney function in treated animals. To
test this hypothesis we used a well-established renal ische-
mia reperfusion injury mouse model23 to determine if fol-
lowing an I/R injury, rat PCs could facilitate restoration of
normal tissue architecture in damaged kidneys and critically
restore renal function.
Materials and Methods
Isolation, maintenance, and characterization of
pancreas-derived PCs
Pancreatic ductal tissue was isolated from 12-month-old
Albino Swiss (Glasgow) rats. Tissue was micro-dissected
and minced, prior to seeding in CMRL-1066 medium (In-
vitrogen, Paisley, UK). The PCs emerged as a confluent
monolayer after approximately 5 weeks in culture. These
were then harvested and washed in phosphate-buffered
saline (PBS). PCs were maintained in culture in 20mL of
CMRL-1066 medium supplemented with 10% fetal bovine
serum (FBS; Sigma, Poole, UK), 2mM glutamate, 1.25mg/
mL amphotericin B, and 100U/mL penicillin, 100 lg/mL
streptomycin (all Invitrogen, Paisley, UK) in T75 culture
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flasks with 0.2-lm filter caps (Corning, UK) at 37C in a 5%
CO2 atmosphere.
PCs were comprised of a mixed CD90 cytotype, positive
for expression of c-met, nestin, CD147, CD44, CD49f, and
CD71 and negative for CD31, CD34, CD45, CD105, CD73,
and c-kit expression.21
Renal ischemia model
For this model, female C57BL/6 mice were used, and the
experimental details are described fully in Hochegger et al.23
In this instance, animals underwent 30min of renal ischemia,
applied via renal clamping.
PC administration
Adult rat pancreas derived PCs were administered intra-
venously (i.v.) via the tail vein to subject mice (n = 14) fol-
lowing an ischemic period of 30min. Within this group there
were three different treatment regimens. The first group
(group A, n = 5) had 1.5 · 106 PCs (in a volume of 500 lL of
saline) injected 24 h after surgery. A second injection of
1.5 · 106 PCs was administered to the mice 1 week later. The
second group (group B, n = 5) received two injections of
1.5 · 106 PCs, 24 h after surgery. The final treatment group
(group C, n = 4) was treated with 1.5 · 106 PCs immediately
after surgery. They received a second injection of 1.5 · 106
cells 1 week later.
Controls comprised a group that had no surgery per-
formed on them (untreated healthy controls n= 6) and ani-
mals that were subjected to an ischemic event, but were left
untreated (saline controls, ischemia, no treatment, n = 6).
These animals were injected with 500 lL of saline into their
tail vein 24 h after surgery.
Assessment of renal function
Blood samples were taken from mice 14 days post-
ischemic event, and serum creatinine levels were measured
using a creatinine autoanalyzer (Beckman Coulter, Fullerton,
CA) to derive a measure of renal function.
Assessment of histological injury
Kidney tissue was fixed in buffered 4% formalin and then
embedded in paraffin wax. The kidneys were sectioned at
5 lm and stained with Periodic Acid Schiff (PAS) prior to
examination by light microscopy.
Immunohistochemistry
Kidneys from PC-treated and control mice were removed,
snap-frozen in liquid nitrogen, and embedded in Tissuetek
OCT compound. Both immunohistochemistry (IHC) and his-
toscore analysis were performed blindly on the tissue sections,
i.e., the treatment group was unknown. Fixed frozen sections
were rehydrated in PBS for 5min. Endogenous peroxidase
was quenched by incubating sections in 3% hydrogen per-
oxide (H2O2) for 10min. Blocking was performed by incu-
bating sections in 20% goat serum in Tris-buffered saline (TBS)
for 1 h at 25C. Tissue sections were incubated with 2lg/mL
p21 Ab (Clone C-19, Santa Cruz Biotechnology, Inc), 8lg/mL
p16ink4a Ab (Clone M-156, Santa Cruz Biotechnology, Inc), or
20l/mL Ki67 (Abcam) in Antibody Diluent (Dako) overnight
at 4C. In each run, negative and positive controls were in-
cluded. Signal was visualized using a goat anti-rabbit sec-
ondary antibody (Dako, 1:200) for 1 h at 25C followed by 3,
3¢-diaminobenzidine (DAB; Vector Laboratories).
Terminal deoxynucleotidyl transferase
dUTP nick end-labeling assay (TUNEL)
Apoptotic cells were identified within the tissue using the
ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit
(Chemicon) following the manufacturer’s instructions.
Briefly, fixed frozen sections were re-hydrated in PBS for
5min. Slides were then incubated with 20 lg/mL Proteinase
K solution for 15min at 25C, treated with 3% H2O2 for
5min, followed by equilibrium buffer for 10min. Slides were
then incubated with terminal deoxynucleotidyl transferase
(TdT) for 1 h before being washed and then treated with anti-
digoxigenin for 30min. Signal was visualized using DAB.
Histoscore analysis
To assess the expression of the various senescence- and
apoptosis-related markers in the kidney tissue, a semi-
quantitative weighted histoscore method was employed as
described previously.24,25 Briefly the intensity of cytoplasmic
and nuclear staining was categorized as negative (0), weak
(1), moderate (2), and strong (3), and the percentage of cells
within each category was estimated. The histoscore was
calculated using the following formula: Histoscore = 0 ·%
negative cells + 1 ·% weakly stained cells+ 2·% moderately
stained cells + 3 ·% cells stained strongly. The histoscore
ranged from a minimum of zero to a maximum of 300. To
assess for Ki67 staining nuclei, the percentages of positive
and negative nuclei were determined. Cytoplasmic and nu-
clear staining for p21, p16ink4a, Ki67, and TdT dUTP nick
end-labeling assay (TUNEL) were scored blindly by two
independent scorers.
Fluorescence in situ hybridization
To track the transplanted cells, we used a xenogeneic
model in which male rat PCs were given to female C57BL/6
mice; this allowed us to distinguish rat PCs from the host
mouse cells via the detection of the rat Y chromosome. Fro-
zen sections were rehydrated in PBS, then pretreated with
1M sodium thiocyanate at 80C for 20min. Tissue digestion
was performed by treating sections with pepsin for 25min at
37C. Slides were then treated with 0.2% glycine for 5min,
then washed in TBS and incubated with 4% paraformalde-
hyde for 5min. A probe to detect rat Y chromosome (Rat
YCy3/12FITC, Cambio) was used. Before use, the probe was
denatured at 65C for 10min. The tissue was denatured in
denaturation solution at 65C for 1.5min, and then incu-
bated in ice-cold ethanol for 2min. Tissues were then de-
hydrated through a series of graded alcohols, before 10 lL
of probe was added to each section. Probe and tissue were
hybridized for 10min at 80C and then overnight at 42C.
Slides were then washed in post-hybridization wash buffer
for 5min at room temperature, followed by a wash at 72C
for 2min. Slides were allowed to air dry before being
mounted onto coverslips using VECTASHIELD (Vector).
The percentage of PCs present within the treated mice
kidneys was then calculated, by determining the total
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number of cells and the number of Rat Y/12-positive cells
present within the tissue.
Statistical analysis
t-Tests were performed to establish any differences in the
serum creatinine levels and expression levels of the senescent
and apoptotic immunohistochemical markers for the various
treatment groups.
Results
PCs stimulate improved kidney function
following I/R injury
We observed significant improvement in kidney function
in PC-treated animals versus saline-treated controls, as
measured by serum creatinine (SC) levels 14 days after the
I/R injury. PC-treated groups A (mean SC = 0.13mg/dL), B
(0.13mg/dL), and C (0.14mg/dL) all had significantly lower
SC levels than the saline-treated control group (0.23mg/dL)
( p= 0.005, p = 0.002, p= 0.01, respectively; Fig. 1). There was
no significant difference between the three PC-treated
groups and the untreated control (no ischemia) mice. How-
ever, the saline-treated group of mice had significantly
higher SC levels than the untreated mice (0.23 vs. 0.10mg/
dL, p< 0.001). Despite the different PC doses and treatment
times, there was no significant difference in the SC levels of
the three different PC-treated groups.
PCs facilitate repair of kidney tissue damage
following I/R injury
Assessment of the expression of p16ink4a was used to
provide a molecular correlate of renal function, as deter-
mined by SC levels. We and others have previously dem-
onstrated that p16ink4a is a superior marker for the
assessment of renal function.4,5 p16ink4a expression was sig-
nificantly lower in the kidneys of PC-treated mice than those
mice treated with saline ( p = 0.009; Fig. 2A, 2B). No signifi-
cant difference in the expression levels of p16ink4a was ob-
served between the untreated mice and the PC-treated mice
(Fig. 2A,B). These observations are consistent with kidneys of
PC-treated animals having less damage and hence fewer
senescent cells present than the saline-treated animals. PCs
thus appear to facilitate tissue repair in the kidney.
Expression of p21 and TUNEL did not differ between the
PC-treated animals and the two control groups of mice 14
days after ischemia (Fig. 2A,B). This result is expected as
changes in p21 expression and apoptosis are known to occur
earlier than the 14-day time point in this model.
Determination of Ki67 was undertaken to assess the extent
of ongoing cellular proliferation at the end of the experiment
(day 14). No significant difference in the Ki67 levels was
observed between untreated healthy controls and PC-treated
animals. Ischemic controls (saline treatment) expressed
higher levels of Ki67 at day 14 than untreated animals
( p= 0.029; Fig. 2A, 2C), suggesting continued proliferation in
FIG. 1. Rat pathfinder cell (PC) treatment improves renal function in mice subject to ischemia. Histogram depicting serum
creatinine (SC) levels as a measure of renal function at the end point of the experiment (t=14 days), in untreated controls (n=6), the
different ischemia and PC-treated animals (n=5, n=5, n=4) and ischemia and no treatment (saline) controls (n=6). The serum
creatinine levels were higher in ischemia and no treatment animals in comparison to the three PC-treated groups (p=0.005, p=0.002,
and p=0.01) and the untreated control (p<0.001). There were no significant differences in serum creatinine levels between the three
PC-treated groups or between the PC-treated groups and untreated controls. *Statistically significant difference p<0.05.
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the ischemic animals to compensate for the absence of ex-
ternal stimuli to repair the damaged kidneys.
The findings that PC treatment facilitates repair of kidney
damage induced by ischemia is further supported by histo-
logical analysis of the kidneys (Fig. 3). Analysis of kidneys
stained with PAS indicates that PC-treated animals displayed
normal histology and renal tissue morphology.
Repair and restoration of kidney function is due
to PC-stimulated host tissue regeneration
rather than PC differentiation
To establish whether the observed repair of the ischemic
damaged kidneys was a result of host tissue regeneration, PC
differentiation, or a combination of both, FISH experiments
FIG. 2. (A) Assessment of cellular bioaging in pathfinder cell (PC)-treated animals and controls following ischemia. Re-
presentative pictures of p16ink4A, p21, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), and Ki67 IHC
staining in kidney tissue from untreated controls, ischemia and saline-treated animals, and ischemia and PC-treated animals.
(B) Histogram depicting average histoscores for p16ink4A, p21, and TUNEL expression in untreated controls, ischemia and PC-
treated animals, and ischemia and no treatment (saline) controls. There was significantly less p16ink4A expression detected in the
kidneys of PC-treated animals post-ischemia/reperfusion (I/R) event in comparison to those from saline-treated ischemic
controls ( p= 0.009). (C) Histogram depicting the average percentage of Ki67-positive nuclei in untreated (healthy) controls,
ischemia and PC-treated animals, and ischemia and no treatment (saline) controls. *Statiscally significant difference p< 0.05.
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were performed to detect the presence of any male rat cells
(PCs or PC-derived) within the kidneys of the female C57Bl/
6 mice.
Mice from each PC-treated group were randomly selected
for FISH analysis (5 kidney tissue sections per animal). De-
tection rate of the xenogeneic signal was low in all PC-
treated animals (0.02%). These observations are consistent
with the enablement of regeneration of host (mouse) kidney
tissue by rat PCs (Fig. 4), as opposed to direct participation in
rebuilding renal tissue. As we have no information about the
frequency of PC division, we do not know if these signals are
from surviving original cells or from progeny of these cells.
Consequently, we do not make any statements concerning
survival of the original cells.
FIG. 2. Continued.
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Discussion
We have demonstrated that PCs derived from the adult
rat pancreas facilitate repair of damaged mouse kidneys and
restoration of kidney function following severe ischemic in-
sult. Repaired kidneys appear histologically normal and
display reduced biological age compared to untreated is-
chemic kidneys, as determined by p16ink4a expression levels
in the repaired organ. Significantly, the repaired tissue was
overwhelmingly mouse (host) in origin. Rat cells were de-
tected at a maximal frequency of less than 0.02% in treated
animals. This is consistent with previous observations in
streptozotocin model of mouse diabetes.22 To our knowl-
edge, this is the first demonstration of an adult cell type
derived from pancreatic tissue fulfilling such a role and the
first demonstration of this in a xenogenic setting.
PC-treated animals were shown to have significantly
lower serum creatinine levels than saline-treated controls
after I/R injury. Fourteen days post-ischemia, serum creati-
nine levels were restored to within a normal range (SC <
0.15mg/dL). This restoration of function was coincident
with restoration of normal kidney histology and a decrease
in the number of senescent and damaged cells present within
the kidney tissue of PC-treated animals in comparison to
saline-treated control mice.
Saline-treated controls exhibited a higher number of cells
expressing p16ink4a than those observed in PC-treated ani-
mals, consistent with DNA damage induced by ischemia.
Previously, it has been shown that ischemic injuries up-
regulate expression of cyclin-dependent kinase inhibitors
such as p21 and p16ink4a.23,26–28
Additionally, p16ink4a has been identified as a biomarker
for pre-transplant prediction of renal function post-transplant.
Higher levels of p16ink4a expression are associated with poorer
function as measured by serum creatinine and urine protein-
to-creatinine ratio (UPCR) levels at 6 months and 1 year post-
transplant.29,30 This correlates with the findings from this
study that control mice that presented with higher se-
rum creatinine levels also exhibited higher expression levels
of p16ink4a.
Within the time course of this experiment, we would have
expected to see an initial rise in p21, peaking by day 7, then
reducing to control levels by day 14, with a correlated in-
crease in p16ink4a expression from day 7, peaking at day 14.28
Our observations on p21 expression at day 14 post-ischemia
are consistent with this, because we observed no significant
FIG. 3. Histological examination of kidneys from pathfinder cell (PC)-treated mice and controls. Light microscopy showing
Periodic Acid Schiff (PAS) staining of representative cortical areas from untreated control kidney (a), ischemic kidney treated
with PCs (b), and untreated ischemic kidney (c) Arrows in c indicate increased casts and brush border loss.
FIG. 4. Fluorescence in situ hybridization (FISH) detection for the rat Y chromosome, corresponding to pathfinder cells
(PCs) or PC-derived cells, in the kidneys of mice subject to renal ischemia and treated with rat PCs. White arrows indicate
detection of the rat Y chromosome. Scale bar, 25lm.
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differences between the PC-treated group and controls. We
also observed no difference in the levels of apoptotic cells, as
measured by the TUNEL assay, between PC and control
animals. As for p21 expression, this is because apoptosis in
this model would have finished before day 14 when the mice
were taken for analysis.28
The mechanism by which PCs contribute to the repair and
regeneration process remains to be determined. There are at
least five possible modes of action that may be considered in
this respect. First, the decreased levels of p16ink4a observed in
PC-treated animals may indicate that PCs have solely a
protective role against ischemic AKI. Second, the cells are
recruited to the damaged kidney and differentiate into the
required renal cell types. Third, the injected cells fuse with
existing host cells to repair any damage. Fourth, the cells
release paracrine/endocrine signals that stimulate repair
processes without actually becoming engrafted into the host
tissue. A fifth possibility is that the PCs stimulate endoge-
nous stem cells present within the host kidney, or a differ-
entiated cell type, to regenerate kidney tissue. These latter
two options may not necessarily be mutually exclusive and
either or both may be extant in the repair process.
In considering the first possible mechanism, while this is a
formal possibility, it is not in keeping with previous data on
pancreatic repair, where xenogenic PCs were responsible for
a paracrine mediated developmental recapitulation of is-
lets,22 nor with repair of ischaemic cardiac damage
(McGlynn et al., in preparation). It is not however, mutually
exclusive from other possible mechanisms.
Options two and three seem unlikely from our results and
those of other studies to be the main modes of action un-
dertaken by PCs. If the PCs were to be recruited to the
damaged organ, engrafted within the tissue, and subse-
quently differentiated into renal epithelial cells, it would be
expected that the detection rate of these cells, or their prog-
eny, within the repaired kidney would be relatively high. In
our xenogenic model, the detection rate for the male rat PCs
was very low (0.02%). The overwhelming majority of cells
present within the kidney were of host origin. Given the low
frequency of PCs present, it seems unlikely that they operate
by differentiating and populating the kidney or by forming
cell fusions with the host cells. This is in agreement with
findings from our previous diabetes mouse model that in-
dicated that the overwhelming majority of the regenerated
islet tissue was host in origin.22 Therefore, it is likely that cells
already present within the kidney are stimulated to regenerate
by the presence of the PCs. Whether these cells are differen-
tiated renal cells or renal stem/progenitor cells remains to be
determined. At least one report has suggested that differen-
tiated tubular epithelial cells that survive an ischemic event
are responsible for regenerating almost all of the new tubular
epithelial cells.31 The rationale for this is that there is a large
reserve of these cells in the G1 phase that enables them to elicit
a proliferative response when activated.31–33
More recently, it has been reported that the repair of renal
proximal tubules is facilitated by self-duplication of differ-
entiated epithelial cells and not by intra-tubular progenitor
cells, as previously suggested. This same study also reports
that the cells most likely to be involved in the repair process
are the result of dedifferentiation/redifferentiation events.34
It has also been reported that repair of damaged renal epi-
thelial cells is initiated when the tubular epithelial cells begin
to proliferate and that this is characterized by the detection of
mesenchymal markers, usually only detectable during ne-
phrogenesis. It has been hypothesized that following injury
tubular cells may undergo an epithelial-to-mesenchymal
transition31,35 to enable repair. This proposed reprogramming
of the tubular cells is interesting and parallels our previous
findings from the use of PCs to treat diabetic mice.22 In the
regenerated pancreata of PC-treated mice, we detected the
Insulin (Ins) I transcript, which suggested that developmental
reprogramming had occurred as part of the repair process.22
Ins I is normally only produced during embryonic develop-
ment in the mouse. Such developmental recapitulation is
again in keeping with other observations in the field.
It remains to be determined if PCs act solely by paracrine
signaling to enable any effect in the ischemic kidney and, or,
whether this process incorporates dedifferentiation/re-
differentiation of terminal renal cell types. Evidence from the use
of MSCs in vivo suggests that they function in repairing renal
damage not by differentiating themselves but by inhibiting pro-
inflammatory cytokines and stimulating anti-inflammatory cy-
tokines.8 This hypothesis is supported by the observation of up-
regulation of inflammatory responses following organ I/R in-
jury, coincident with an increase in cellular apoptosis, reactive
oxygen species generation, and mitochondrial damage.17
A further consideration for the mechanism of PC-
mediated renal repair is the involvement of a PC micro-
secretome. The release of MSC-derived microvesicles (MV)
and the associated transfer of MV mRNA has already been
demonstrated to activate the proliferation of tubular epithelial
cells and to protect against both acute and chronic kidney
injury induced by I/R injury.36,37 The release of these secre-
tory factors by the transplanted cells and not the engraftment
and differentiation of the cells is consistent with a paracrine
mediated repair of the kidney. Investigation of the factors
secreted by the PCs is ongoing. The data presented here and
in our previous study22 have offered possible mechanisms
that may explain the action of PCs. However, their definitive
mode of action remains to be determined. Further work is
currently ongoing to ascertain how PCs stimulate the repair
and regeneration processes in damaged tissue.
This study has clearly demonstrated that pancreatic-derived
PCs enable functional recovery in mouse kidneys following an
ischemic event. Our observations replicate those observed in an
streptozotocin-induced diabetes model, whereby PCs repaired
the pancreatic islets to such an extent that the effects of the
diabetes were reversed and normal glycemia was restored.22
Consequently, we believe the use of PCs is neither restricted to
their tissue, nor species of origin and that their use may be
applicable to a wide range of tissue damage. As such, they
appear to have great translational potential.
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